// App-Quantinova.ai

1866 : HER3 targeting sensitizes HNSCC to cetuximab - evidence from cell line and patient derived xenograft (PDX) models

Researchers

Presenter

  • Dongsheng Wang

Principal Investigators

  • Guoqing Qian

  • hongzheng zhang

  • kelly R. Magliocca

  • sreenivas nannapaneni

  • zhengjia chen

  • mihir R. patel

  • Mark W. El-Deiry

  • J.trad Wadsworth

  • dong M. Shin

  • fadlo R. khuri

  • Nabil F. Saba

  • Zhuo G. chen

Medical Centers

  • Winship Cancer Institute of Emory University, Atlanta, GA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • erb-b2 receptor tyrosine kinase 2

  • Extracellular signal-regulated kinase

  • PI3K/AKT

Drug/Treatment

  • Erbitux

  • Seribantumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved